Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.769 EUR | +2.26% | -3.88% | +78.84% |
Mar. 11 | Sensorion: study results in hearing loss | CF |
Mar. 11 | Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+78.84% | 224M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |
- Stock
- Equities
- Stock Sensorion - Euronext Paris
- News Sensorion
- Sensorion Wins Regulatory Nod to Launch Mid-Stage Study of Cisplatin-Induced Hearing Loss Drug